Expression of tenascin in hamster buccal pouch mucosa during experimental carcinogenesis.
Experimental carcinogenesis by topical application of 7,12-dimethylbenz(a)anthracene (DMBA) in hamster buccal pouch mucosa was evaluated for expression of tenascin, an extracellular matrix glycoprotein expressed at the epithelial-mesenchymal interface during embryonic and fetal development, wound healing and in the stroma of various neoplastic lesions, by using immunohistochemical methods. The buccal pouch mucosa in normal hamsters showed immunoreactive tenascin either as a linear delicate band or without reactivity at the immediate vicinity of the basement membrane. During carcinogenesis, in the second to fourth week of application of DMBA, the hyalinous changes in the submucosal connective tissue had a weak but diffuse immunoreactivity for tenascin. The hyperkeratinised and hyperplastic mucosa following 5 weeks of application of DMBA showed focal areas of enhanced expression in the vicinity of the basement membrane. Subsequently, specimens showing hyperplasia, dysplasia, carcinoma in situ and invasive carcinomas had comparatively more widespread stromal immunoreactivity where the extent of enhanced reactivity positively correlated with the advancing lesion. These results compared with the results of expression in human normal mucosa, leukoplakia and squamous cell carcinoma of the oral cavity (Shrestha et al., Oral Oncol, Eur J Cancer 1994, 30, 132-137) suggest that the expression of tenascin in experimental carcinogenesis of hamster buccal pouch mucosa, as a model, faithfully mimics the same in human oral mucosa.
Lee
S K
SK
Department of Pathology, Seoul National University College of Medicine, Korea.
Park
S C
SC
Chi
J G
JG
Sakamoto
F
F
Shrestha
P
P
Mori
M
M
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002278:Carcinoma in Situ / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D002610:Cheek; D006224:Cricetinae; D004195:Disease Models, Animal; D008297:Male; D008647:Mesocricetus; D009061:Mouth Mucosa / Q000378:metabolism*; D009062:Mouth Neoplasms / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D011230:Precancerous Conditions / Q000378:metabolism; D019063:Tenascin / Q000096:biosynthesis*
D009363:Neoplasm Proteins; D019063:Tenascin; D015127:9,10-Dimethyl-1,2-benzanthracene